SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) released its quarterly earnings data on Thursday. Here are the key takeaways from SAB Biotherapeutics’ conference call:Get SAB Biotherapeutics alerts:SAFEGUARD enrollment is accelerating , with more than 60 sites actively recruiting and increased screening and randomization. SAB Biotherapeutics Price PerformanceShares of SABS stock traded up $0.05 during trading hours on Friday, hitting $3.90. SAB Biotherapeutics has a fifty-two week low of $1.85 and a fifty-two week high of $5.15. Featured StoriesReceive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.